Seeking Alpha

Peregrine Pharma starts Phase 3 immunotherapy trial in lung cancer

  • Peregrine Pharmaceuticals (PPHM +2.2%) announces the initiation of a Phase 3 trial of a bavituximab/ docetaxel combo in second-line NSCLC.
  • OS is the primary endpoint. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)